Kehm R, Vilfranc C, McDonald J, Wu H
Int J Environ Res Public Health. 2025; 22(1).
PMID: 39857573
PMC: 11765400.
DOI: 10.3390/ijerph22010120.
Almohaid S, Akhtar S
BMC Cancer. 2024; 24(1):694.
PMID: 38844890
PMC: 11157712.
DOI: 10.1186/s12885-024-12409-0.
Johnson S, Bao H, McMahon C, Chen Y, Burr S, Anderson A
Nat Commun. 2024; 15(1):4847.
PMID: 38844467
PMC: 11156938.
DOI: 10.1038/s41467-024-49224-x.
Mahmoudi A, Jalili A, Butler A, Aghaee-Bakhtiari S, Jamialahmadi T, Sahebkar A
J Clin Exp Hepatol. 2024; 14(4):101365.
PMID: 38433957
PMC: 10904918.
DOI: 10.1016/j.jceh.2024.101365.
Gallagher K, Bernstein I, Collings C, Main D, Ahmad G, Naughton S
J Anim Sci Biotechnol. 2024; 15(1):13.
PMID: 38281954
PMC: 10823655.
DOI: 10.1186/s40104-023-00973-7.
Unraveling the mechanisms of trans-cinnamic acid in ameliorating non-alcoholic fatty liver disease.
Solanki N, Patel R
Am J Transl Res. 2023; 15(9):5747-5756.
PMID: 37854239
PMC: 10579026.
Dietary inflammatory potential is associated with higher odds of hepatic steatosis in US adults: a cross-sectional study.
Yang H, Zhang T, Song W, Peng Z, Zhu Y, Huang Y
Public Health Nutr. 2023; 26(12):2936-2944.
PMID: 37807893
PMC: 10755422.
DOI: 10.1017/S1368980023001970.
Hyaluronic acid-graphene oxide quantum dots nanoconjugate as dual purpose drug delivery and therapeutic agent in meta-inflammation.
Sarkar K, Bank S, Chatterjee A, Dutta K, Das A, Chakraborty S
J Nanobiotechnology. 2023; 21(1):246.
PMID: 37528408
PMC: 10394801.
DOI: 10.1186/s12951-023-02015-w.
Endocrine disrupting chemicals: A promoter of non-alcoholic fatty liver disease.
Chen Y, Wang Y, Cui Z, Liu W, Liu B, Zeng Q
Front Public Health. 2023; 11:1154837.
PMID: 37033031
PMC: 10075363.
DOI: 10.3389/fpubh.2023.1154837.
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro.
Shatta M, El-Derany M, Gibriel A, El-Mesallamy H
Mol Cell Biochem. 2022; 478(8):1689-1704.
PMID: 36495373
PMC: 10267014.
DOI: 10.1007/s11010-022-04619-6.
Relationships of 25-hydroxyvitamin D levels and non-alcoholic fatty liver disease in obese children: A possible strategy to promote early screening of NAFLD.
Manoppo J, Pateda V, Prayogo C, Langi F, Nurkolis F, Tsopmo A
Front Nutr. 2022; 9:1025396.
PMID: 36407527
PMC: 9667029.
DOI: 10.3389/fnut.2022.1025396.
The Association Between Age and Systemic Variables and the Longitudinal Trend of Intraocular Pressure in a Large-Scale Health Examination Cohort.
Asaoka R, Obana A, Murata H, Fujino Y, Omoto T, Aoki S
Invest Ophthalmol Vis Sci. 2022; 63(11):22.
PMID: 36301531
PMC: 9624273.
DOI: 10.1167/iovs.63.11.22.
Therapies for non-alcoholic fatty liver disease: A 2022 update.
Shen K, Singh A, Modaresi Esfeh J, Wakim-Fleming J
World J Hepatol. 2022; 14(9):1718-1729.
PMID: 36185717
PMC: 9521452.
DOI: 10.4254/wjh.v14.i9.1718.
Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia.
Moretti R, Giuffre M, Croce L, Gazzin S, Tiribelli C
J Pers Med. 2022; 12(7).
PMID: 35887603
PMC: 9323787.
DOI: 10.3390/jpm12071106.
Just Drink a Glass of Water? Effects of Bicarbonate-Sulfate-Calcium-Magnesium Water on the Gut-Liver Axis.
Gravina A, Romeo M, Pellegrino R, Tuccillo C, Federico A, Loguercio C
Front Pharmacol. 2022; 13:869446.
PMID: 35837275
PMC: 9274271.
DOI: 10.3389/fphar.2022.869446.
Trends in insulin resistance: insights into mechanisms and therapeutic strategy.
Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H
Signal Transduct Target Ther. 2022; 7(1):216.
PMID: 35794109
PMC: 9259665.
DOI: 10.1038/s41392-022-01073-0.
Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology.
Bertran L, Eigbefoh-Addeh A, Portillo-Carrasquer M, Barrientos-Riosalido A, Binetti J, Aguilar C
Biomedicines. 2022; 10(6).
PMID: 35740337
PMC: 9219880.
DOI: 10.3390/biomedicines10061315.
Characterization and Roles of Membrane Lipids in Fatty Liver Disease.
Welch M, Secunda C, Ghimire N, Martinez I, Mathus A, Patel U
Membranes (Basel). 2022; 12(4).
PMID: 35448380
PMC: 9025760.
DOI: 10.3390/membranes12040410.
Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.
Santos J, de Maio M, Lemes M, Fornari Laurindo L, Dos Santos Haber J, Bechara M
Int J Mol Sci. 2022; 23(1).
PMID: 35008925
PMC: 8745668.
DOI: 10.3390/ijms23010498.
The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Shabani-Borujeni M, Modaresi S
Front Pharmacol. 2021; 12:732496.
PMID: 34803681
PMC: 8595299.
DOI: 10.3389/fphar.2021.732496.